For the quarter ending 2026-03-31, APGE has $1,293,654K in assets. $37,861K in debts.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 451,797 | 131,549 | 107,914 | 124,192 |
| Marketable securities | 608,088 | 598,643 | 419,375 | 381,228 |
| Prepaid expenses and other current assets | 13,912 | 11,166 | 12,808 | 10,702 |
| Total current assets | 1,073,797 | 741,358 | 540,097 | 516,122 |
| Long-term marketable securities | 198,354 | 172,730 | 61,640 | 115,769 |
| Property and equipment, net | 5,280 | 5,688 | 6,032 | 6,438 |
| Right-of-use asset, net | 7,707 | 8,687 | 9,646 | 10,586 |
| Other non-current assets | 8,516 | 8,671 | 8,744 | 8,857 |
| Total assets | 1,293,654 | 937,134 | 626,159 | 657,772 |
| Accounts payable | 1,237 | 1,221 | 376 | 5,678 |
| Lease liability | 3,138 | 3,504 | 4,079 | 4,025 |
| Accrued expenses and other current liabilities | 28,577 | 23,181 | 29,592 | 21,848 |
| Total current liabilities | 32,952 | 27,906 | 34,047 | 31,551 |
| Lease liability, net of current | 4,909 | 5,345 | 5,774 | 6,820 |
| Total liabilities | 37,861 | 33,251 | 39,821 | 38,371 |
| Common stock 0.00001 par value, 400,000,000 authorized, 75,323,726 issued and 74,882,396 outstanding as of march 31, 2026 400,000,000 authorized, 69,038,943 issued and 68,401,349 outstanding as of december 31, 2025 | 1 | 1 | 1 | 1 |
| Additional paid-in capital | 1,892,411 | 1,464,561 | 1,077,681 | 1,046,066 |
| Accumulated other comprehensive income (loss) | -749 | 1,080 | 1,028 | 685 |
| Accumulated deficit | -635,870 | -561,759 | -492,372 | -427,351 |
| Total stockholders' equity | 1,255,793 | 903,883 | 586,338 | 619,401 |
| Total liabilities and stockholders' equity | 1,293,654 | 937,134 | 626,159 | 657,772 |
Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics, Inc. (APGE)